Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 USD | -3.97% | -11.92% | -87.76% |
Sales 2024 * | 39.35M 3.29B | Sales 2025 * | 58.17M 4.86B | Capitalization | 73.06M 6.1B |
---|---|---|---|---|---|
Net income 2024 * | -120M -10.02B | Net income 2025 * | -77M -6.43B | EV / Sales 2024 * | -1.38 x |
Net cash position 2024 * | 127M 10.64B | Net cash position 2025 * | 54.53M 4.55B | EV / Sales 2025 * | 0.32 x |
P/E ratio 2024 * |
-0.67
x | P/E ratio 2025 * |
-1.28
x | Employees | 166 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.02% |
Latest transcript on Marinus Pharmaceuticals, Inc.
1 day | -3.97% | ||
1 week | -11.92% | ||
Current month | -5.67% | ||
1 month | -83.56% | ||
3 months | -86.83% | ||
6 months | -77.68% | ||
Current year | -87.76% |
Managers | Title | Age | Since |
---|---|---|---|
Scott Braunstein
CEO | Chief Executive Officer | 60 | 05/18/05 |
Steven Pfanstiel
DFI | Director of Finance/CFO | 51 | 12/21/12 |
Joseph Hulihan
CTO | Chief Tech/Sci/R&D Officer | 68 | 06/19/06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Mayleben
BRD | Director/Board Member | 63 | 01/08/01 |
Scott Braunstein
CEO | Chief Executive Officer | 60 | 05/18/05 |
Elan Ezickson
BRD | Director/Board Member | 60 | 12/19/12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.96% | 11 M€ | -6.03% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
10/24/10 | 1.33 | -3.97% | 2,058,410 |
09/24/09 | 1.385 | -3.15% | 1,221,211 |
08/24/08 | 1.43 | -8.92% | 2,402,294 |
07/24/07 | 1.57 | +6.08% | 1,304,147 |
06/24/06 | 1.48 | -1.99% | 1,574,489 |
Delayed Quote Nasdaq, May 11, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.76% | 73.06M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- MRNS Stock